Home Compare NBIX vs R3NK.DE
Stock Comparison · Comparison

Neurocrine Biosciences vs RENK Group: Which Stock Looks Stronger in 2026?

Neurocrine Biosciences holds the cleaner structural position, with the lead spread across stability and growth. RENK does not offset that deficit through any equally strong structural edge elsewhere. On the market side, Neurocrine Biosciences is in better shape — its trend is intact while RENK's trend has broken down. That puts structure and market broadly in agreement — Neurocrine Biosciences's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (NBIX: Russell 1000, R3NK.DE: STOXX 600).

Updated 2026-05-17

The lead is spread across stability and growth, rather than sitting in one isolated gap. The overall score gap is 24 points in favour of Neurocrine Biosciences, Inc..

Trajectory Similarity
0.69
Moderately similar
Peer-set rank: #12
within Neurocrine Biosciences, Inc.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.

The match is driven mainly by capital structure and recent revenue growth.

Similarity drivers
capital structurerecent revenue growth
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
NBIX
Neurocrine Biosciences, Inc.
66
Peer-Score
Signal qualitylow
Peer basis: Russell 1000
vs
R3NK.DE
RENK Group AG
42
Peer-Score
Signal qualitylow
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: NBIX vs R3NK.DE Profitability 33 40 Stability 74 31 Valuation 73 40 Growth 98 61 NBIX R3NK.DE
Gap Ranking
#1 Stability +43
#2 Growth +37
#3 Valuation +33
#4 Profitability +7
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for NBIX and R3NK.DE Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer NBIXR3NK.DE Relative valuation Structural strength

Neurocrine Biosciences, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
On stability, Neurocrine Biosciences, Inc. ranks near the top of the group; RENK Group AG sits in the weaker half.
Growth
On growth, the same pattern holds: both are strong, but Neurocrine Biosciences, Inc. still leads clearly.
Stability — Dominant Gap
NBIX
74
R3NK.DE
31
Gap+43in favour of NBIX

The clearest distance comes from a steadier profile over time.

What else supports the lead

Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.

What this means for the comparison

The lead is built on both stability and growth, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the NBIX vs R3NK.DE comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar stability-and-growth comparisons

Explore how NBIX and R3NK.DE each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.